Institution
Medical University of South Carolina
Education•Charleston, South Carolina, United States•
About: Medical University of South Carolina is a education organization based out in Charleston, South Carolina, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 23436 authors who have published 45440 publications receiving 1769397 citations. The organization is also known as: MUSC & Medical College of the State of South Carolina.
Topics: Population, Poison control, Medicine, Cancer, Stroke
Papers published on a yearly basis
Papers
More filters
University of Toronto1, University of Zurich2, Harvard University3, Queen Mary University of London4, Tufts University5, University of California, San Diego6, Boston University7, Medical University of South Carolina8, University of Helsinki9, Queensland Health10, University of Queensland11, University of California, Riverside12, University of Auckland13, University of Saskatchewan14, Ruhr University Bochum15
TL;DR: There is now strong evidence that increasing vitamin D intake will lower risk of falling and lower fracture risk in older men and women and regulatory agencies in the United States and abroad should review the evidence and reassess their dietary recommendations.
700 citations
TL;DR: The use of the PLCO(M2012) model was more sensitive than the NLST criteria for lung-cancer detection and compared the accuracy of PLCo(M 2012) criteria withNLST criteria to detect lung cancer.
Abstract: Background The National Lung Screening Trial (NLST) used risk factors for lung cancer (e.g., ≥30 pack-years of smoking and <15 years since quitting) as selection criteria for lung-cancer screening. Use of an accurate model that incorporates additional risk factors to select persons for screening may identify more persons who have lung cancer or in whom lung cancer will develop. Methods We modified the 2011 lung-cancer risk-prediction model from our Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to ensure applicability to NLST data; risk was the probability of a diagnosis of lung cancer during the 6-year study period. We developed and validated the model (PLCOM2012) with data from the 80,375 persons in the PLCO control and intervention groups who had ever smoked. Discrimination (area under the receiver-operating-characteristic curve [AUC]) and calibration were assessed. In the validation data set, 14,144 of 37,332 persons (37.9%) met NLST criteria. For comparison, 14,144 highest-risk...
699 citations
University of Göttingen1, City College of New York2, University of São Paulo3, University of Toronto4, Aalborg University5, University of Erlangen-Nuremberg6, Greifswald University Hospital7, Spaulding Rehabilitation Hospital8, Medical University of South Carolina9, University of Pennsylvania10, Technische Universität Ilmenau11, University of Oldenburg12, École Polytechnique Fédérale de Lausanne13, Paris 12 Val de Marne University14, University of New South Wales15, University of Aberdeen16, University of Trento17, University of Lisbon18, University of Kiel19, Technical University of Dortmund20, Ruhr University Bochum21, Ludwig Maximilian University of Munich22, Beth Israel Deaconess Medical Center23, Mannheim University of Applied Sciences24, University of Siena25, The Catholic University of America26, University College London27, University of Copenhagen28, Fukushima Medical University29, Massachusetts Institute of Technology30, University of Tübingen31
TL;DR: Structured interviews are provided and recommend their use in future controlled studies, in particular when trying to extend the parameters applied, to discuss recent regulatory issues, reporting practices and ethical issues.
699 citations
TL;DR: Personalized therapeutic strategies are proposed that addresses HFpEF-specific signaling and phenotypic diversity and target individual steps of systemic and myocardial signaling cascades.
Abstract: Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF, large trials testing neurohumoral inhibition in HFpEF failed to reach a positive outcome. This failure was recently attributed to distinct systemic and myocardial signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling and phenotypic diversity. In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction. The latter affects left ventricular diastolic dysfunction through macrophage infiltration, resulting in interstitial fibrosis, and through altered paracrine signaling to cardiomyocytes, which become hypertrophied and stiff because of low nitric oxide and cyclic guanosine monophosphate. Systemic inflammation also affects other organs such as lungs, skeletal muscle, and kidneys, leading, respectively, to pulmonary hypertension, muscle weakness, and sodium retention. Individual steps of these signaling cascades can be targeted by specific interventions: metabolic risk by caloric restriction, systemic inflammation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxide bioavailability by inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by spironolactone. Because of phenotypic diversity in HFpEF, personalized therapeutic strategies are proposed, which are configured in a matrix with HFpEF presentations in the abscissa and HFpEF predispositions in the ordinate.
698 citations
Medical University of South Carolina1, Wake Forest University2, Emory University3, Indiana University4, Indiana University – Purdue University Indianapolis5, University of Texas Southwestern Medical Center6, Virginia Commonwealth University7, Imperial College Healthcare8, University of Texas MD Anderson Cancer Center9, Case Western Reserve University10
TL;DR: The accuracy of CTC varied considerably between centers and did not improve as the study progressed, suggesting that this method is not yet ready for widespread clinical application.
Abstract: ContextConventional colonoscopy is the best available method for detection
of colorectal cancer; however, it is invasive and not without risk. Computed
tomographic colonography (CTC), also known as virtual colonoscopy, has been
reported to be reasonably accurate in the diagnosis of colorectal neoplasia
in studies performed at expert centers.ObjectiveTo assess the accuracy of CTC in a large number of participants across
multiple centers.Design, Setting, and ParticipantsA nonrandomized, evaluator-blinded, noninferiority study design of 615
participants aged 50 years or older who were referred for routine, clinically
indicated colonoscopy in 9 major hospital centers between April 17, 2000,
and October 3, 2001. The CTC was performed by using multislice scanners immediately
before standard colonoscopy; findings at colonoscopy were reported before
and after segmental unblinding to the CTC results.Main Outcome MeasuresThe sensitivity and specificity of CTC and conventional colonoscopy
in detecting participants with lesions sized at least 6 mm. Secondary outcomes
included detection of all lesions, detection of advanced lesions, possible
technical confounders, participant preferences, and evidence for increasing
accuracy with experience.ResultsA total of 827 lesions were detected in 308 of 600 participants who
underwent both procedures; 104 participants had lesions sized at least 6 mm.
The sensitivity of CTC for detecting participants with 1 or more lesions sized
at least 6 mm was 39.0% (95% confidence interval [CI], 29.6%-48.4%) and for
lesions sized at least 10 mm, it was 55.0% (95% CI, 39.9%-70.0%). These results
were significantly lower than those for conventional colonoscopy, with sensitivities
of 99.0% (95% CI, 97.1%->99.9%) and 100%, respectively. A total of 496 participants
were without any lesion sized at least 6 mm. The specificity of CTC and conventional
colonoscopy for detecting participants without any lesion sized at least 6
mm was 90.5% (95% CI, 87.9%-93.1%) and 100%, respectively, and without lesions
sized at least 10 mm, 96.0% (95% CI, 94.3%-97.6%) and 100%, respectively.
Computed tomographic colonography missed 2 of 8 cancers. The accuracy of CTC
varied considerably between centers and did not improve as the study progressed.
Participants expressed no clear preference for either technique.ConclusionsComputed tomographic colonography by these methods is not yet ready
for widespread clinical application. Techniques and training need to be improved.
697 citations
Authors
Showing all 23601 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Edward Giovannucci | 206 | 1671 | 179875 |
| Ronald Klein | 194 | 1305 | 149140 |
| Peter W.F. Wilson | 181 | 680 | 139852 |
| Yusuke Nakamura | 179 | 2076 | 160313 |
| John J.V. McMurray | 178 | 1389 | 184502 |
| Nora D. Volkow | 165 | 958 | 107463 |
| L. Joseph Melton | 161 | 531 | 97861 |
| Gregg C. Fonarow | 161 | 1676 | 126516 |
| Michael Boehnke | 152 | 511 | 136681 |
| Charles B. Nemeroff | 149 | 979 | 90426 |
| Deepak L. Bhatt | 149 | 1973 | 114652 |
| Clifford R. Jack | 140 | 965 | 94814 |
| Scott D. Solomon | 137 | 1145 | 103041 |
| Karl Swedberg | 136 | 706 | 111214 |
| Charles J. Yeo | 136 | 672 | 76424 |